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Renal hemodynamics in newly presenting non-insulin dependent diabe-
tes mellitus. Little information is available regarding renal hemodynam-
ics in non-insulin dependent diabetics (NIDDMs), despite their numer-
ical significance to renal support programs. Therefore, simultaneous
determination of glomerular filtration rate (GFR) and effective renal
plasma flow (ERPF) (expressed to 1.73 m2 surface area) was performed
in 110 newly presenting normotensive NIDDM5 [mean (SD) age: 52.5
(10.1) years] and compared with 32 normal subjects of similar age range
[age: 52.2 (11.3) years]. Mean (SD) GFR, ERPF and filtration fraction
(FF) for the NIDDMs were: 117(22) mI/mm (range: 74 to 178), 534 (123)
mi/mm and 22.4 (3.0)%, and for the normals: 95 (12) mI/mm (range: 75
to 119), 472 (70) mI/mm and 20.2 (2.2%), respectively. As a group,
NIDDMs demonstrated significantly greater GFR (P <0.001), ERPF(P
< 0.005) and FF (P < 0.001). GFR values above 140 mI/mm were
observed in 16% of the NIDDMs, while 45% had GFRs in excess of
mean 2 SD of the normals. NIDDMs demonstrated a positive
relationship for GFR with ERPF (P < 0.001) and an inverse association
for both GFR and ERPF with age (P < 0.001). Muitivariable regression
analysis revealed ERPF as the strongest explanatory variable for GFR
in the NIDDMs (P < 0.001), followed by age (P < 0.01). Significant
contributions to the regression analysis were not observed for body
mass index, systolic or diastolic blood pressures, glycosylated hemo-
globin nor fasting levels of plasma glucose, cholesterol, HDL-choles-
terol, LDL-choiesterol and triglycerides. Urinary albumin excretion
rates were not correlated with GFR, ERPF or FF. Microalbuminuria
was detected in 7% of the NIDDMs in this study. We conclude that
newly presenting NIDDMs demonstrate a wide range of GFR, unre-
lated to blood pressure, prevailing glycemic parameters or lipid levels.
GFR, ERPF and filtration fraction are greater for the NIDDMs than the
normals, and hyperfiitration is present in a significant proportion of the
NIDDMs.
Nephropathy is a common complication of diabetes mellitus,
affecting 30 to 40% long-term insulin-dependent diabetics (ID-
DMs) diagnosed under the age of 31 years [1, 2]. Structural
changes characteristic of diabetic glomerulopathy also occur in
non-insulin dependent diabetes (NIDDM) and clinical nephrop-
athy occurs in a significant number of cases [3]. The precise
frequency of nephropathy in NIDDM, however, has not been
established, possibly due to the common co-existence of hyper-
tension and macrovascular disease [4—6]. A cumulative inci-
dence of 25% has been reported for nephropathy, defined as
persistent proteinuria, in NIDDMs of disease duration of 20
years [7]. Studies from the USA reveal almost equal numbers of
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IDDMs and NIDDMs patients receiving treatment for end-stage
renal disease (ESRD) [8—101. Indeed, of all new diabetic enroll-
ees into the Medicare ESRD program during 1985, 36% were
over the age of 65 years, suggesting a significant proportion
were NIDDMs [11]. In the United Kingdom, 25 to 35% of
diabetics receiving renal support therapy during the period 1983
to 1985 were NIDDMs [12—14].
Despite the significant numbers of NIDDMs on ESRD pro-
grams, information regarding the early stages of renal dysfunc-
tion in this group of patients, prior to the development of overt
nephropathy, is sparse. The purpose of our study, therefore,
was to determine glomerular filtration rate (GFR) and effective
renal plasma flow (ERPF) in a group of newly presenting
normotensive NIDDMs with no concommitant diseases. The
renal parameters measured in the NIDDMs were compared
with those observed in a group of normal subjects of a similar
age range.
Methods
One hundred and ten (75 male; 35 females) consecutive,
newly presenting and previously untreated, islet cell antibody-
negative Caucasian NIDDMs who were receiving no concom-
mitant medication were recruited from the Diabetic Clinics at
the University Hospital. Diagnosis of NIDDM was made on the
basis of clinical presentation, absence of ketonuria and bio-
chemical classification, according to the WHO criteria [15].
After participating in the present study, patients were com-
menced on dietary treatment, with subsequent addition of oral
hypoglyemic agents as necessary. All patients selected were
normotensive by WHO criteria [161. Patients with possible
pre-existing renal disease, as evidenced by an increased serum
creatinine level (above 120 ILmol/liter), hematuria or proteinuria
on dipstick testing, were excluded from the study. Thirty-two
normal subjects (21 males; 11 females) with no family history of
renal disorders, diabetes or hyperlipidemia, were recruited
from a screening program, including members of staff. The
normal subjects underwent a full clinical examination, routine
hematological and biochemical screening and their normal
glucose tolerance was confirmed according to WHO criteria
[15]. The NIDDMs and normal subjects received no specific
dietary advice prior to the estimation of their renal hemody-
namic parameters. Full informed written consent was obtained
from each subject and the study was approved by the local Area
Health Authority ethics committee.
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GFR and ERPF were determined following an overnight fast.
The study periods commenced at 0800 hours, with the siting of
an intravenous cannula into an ante-cubital fossa vein. The
cannula was connected via a three way tap, for blood sampling,
to a slow running infusion of normal saline (150 mmol/liter).
Thereafter, blood samples were obtained for the estimation of
fasting plasma glucose for both groups of subjects, and fasting
lipid and glycosylated hemoglobin levels for the NIDDMs. At
0900 hours, subjects were administered a single intravenous
injection into a contralateral arm vein, containing 1 megaBe-
querel each of 51Cr-ethylene diamine-tetra-acetic acid (EDTA)
and '251-iodohippurate (Amersham International, UK) for the
simultaneous determination of GFR and ERPF. Following the
administration of the radioisotopes, blood samples were ob-
tained at 44 minutes, 2, 3 and 4 hours. Subjects remained supine
for the entire four hour study period and smoking was not
permitted. Supine systolic and diastolic (phase V) blood pres-
sures were measured during the clearance procedure, to the
nearest 2 mm by means of a random zero mercury sphygmo-
manometer, using an appropriate 15 x 33 cm cuff for obese
patients. Subjects' weight (kg) and standing height (m) were
measured, prior to the study, while they were dressed in indoor
clothes. Body mass index (BMI) was calculated as weight!
[height]2 (kg/rn2). Within one week of renal hemodynamic
measurements, diabetic retinopathy status was assessed in all
patients, using 35 mm retinal photography and fluorescein
angiography following mydriasis. For the purposes of this
study, NIDDMs were classified as those with (defined as
background, pre-proliferative, proliferative changes or macu-
lopathy in one or both eyes) or without any retinopathy.
GFR and ERPF were determined from the plasma clearance
of the respective isotopes [17], and are expressed for 1.73 m2
body surface area. GFR was calculated by bi-exponential
analysis of the four-hour fractional clearance curve for 51Cr-
EDTA, while '251-iodohippurate clearance was analyzed ac-
cording to the method of Tauxe, Dubovsky and Kidd [181.
Filtration fraction (FF%) was calculated as the ratio of GFR to
ERPF. Following careful instruction, the NIDDMs provided a
timed overnight urine collection for the measurement of albu-
min excretion rates (AER), using a sensitive immunochemilu-
minescence technique [19]. Plasma glucose levels were deter-
mined using a glucose oxidase analyzer [201. Total cholesterol
and triglyceride levels were measured by enzymatic techniques
on the Technicon RA 1000 analyzer (Technicon Instruments
Co. Ltd., Basingstoke, UK) [21, 22]. Measurement of HDL-
cholesterol was performed using the same technique, following
heparin manganese precipitation of VLDL- and LDL-choles-
terol [23]. LDL-cholesterol was calculated using the Friedewald
formula [24]. Glycosylated hemoglobin (HbAI) was determined
chromatographically (reference range 5.5 to 8%) [25].
Statistical methods
Statistical analyses were conducted using the Minitab Re-
lease 7 statistical package [261. Comparisons between the
NIDDMS and normals were performed using the Mann-Whit-
ney U test, Bivariate relationships were explored by means of
linear regression analyses. Relationships of AER with renal
hemodynamics were assessed following logarithmic transfor-
mation of the former parameter. Modelling on several variables
simultaneously was performed by multivariable stepwise re-
gression analysis, using appropriate models, with GFR and
ERPF for the NIDDMs as the dependent variables. Signifi-
cances of the regression analyses were assessed by analysis of
variance. Relative contributions of different independent vari-
ables on GFR and ERPF were assessed by analysis of covari-
ance. P values below 0,05 were considered significant. Results
are expressed as mean (sD), unless otherwise stated, with
ranges shown in parenthesis where appropriate.
Results
Mean ages were similar for the groups, at 52.5 (10.1) years for
the NIDDMs and 52.2 (11.3) years for the normals. As ex-
pected, body mass index (BMI) was greater in the NIDDMs at
28.7 (5.1) kg/rn2 compared with 25.5 (3,6) kg/rn2 for the normals
(P < 0.05).
GFR, ERPF and FF for the NIDDMs were 117 (22) mI/mm
(range 74 to 178), 534 (123) ml/min (258 to 821) and 22.4 (3.0)%.
Supine systolic and diastolic blood pressures for the NIDDMs
group were 131(16) and 82 (8) mm Hg. Biochemical parameters
in the NIDDMs were as follows: fasting plasma glucose: 12.4
(3.3) mmol/liter; glycosylated hemoglobin: 11.2 (2.3)%; total
cholesterol: 5.6 (1.4) mmol/liter; HDL-cholesterol: 1.1 (0.9)
mmol/liter; LDL-cholesterol: 3.4 (1.1) mmol/liter: triglycerides:
2.3 (1.1) mrnol/ljter. Total cholesterol values above 6 mmol/liter
were noted in 38 (35%) of the NIDDMs, while 44 (40%) had
triglyceride levels in excess of 2 mmol/liter. In the normal
subjects, GFR, ERPF and FF were 95 (12) mI/mm (75 to 119),
472 (70) mI/mm (352 to 619) and 20.2 (2.2)%. Systolic and
diastolic blood pressures for this group were 123 (13) and 77 (7)
mm Hg. Mean fasting plasma glucose level for the normals was
5.5 (0.6) mmol/liter.
Comparisons between the NIDDMs and the normal subjects
revealed significantly greater GFR in the former group (P <
0.001; Fig. 1). In the NIDDMs, 18(16%) patients demonstrated
GFR values above 140 mI/mm and 49 (45%) demonstrated GFR
values in excess of 120 mi/mm, which corresponds to mean 2
standard deviations for the normal subjects. Similarly, ERPF
was significantly elevated for the NIDDMs compared with the
normals (P < 0.005). As a group, the NIDDMs also demon-
strated significantly higher FF compared with the normals (P <
0.001). Systolic (P < 0.05) and diastolic (P < 0.01) blood
pressures were higher for the NIDDMs than the normals,
despite being within the normotensive range. However, divi-
sion of the NIDDMs into those with GFR above or below mean
2 SD of the normals (120 mI/mm), did not reveal significant
differences in blood pressures between the two groups. Systolic
and diastolic blood pressures for those NIDDMs with GFR
values above 120 mI/mm (N = 49) were 128 (16) and 82 (8)
mm Hg, compared with 132 (17) and 82 (9) mm Hg for those
patients with GFRs below 120 ml/min (N 61).
In the NIDDMs, GFR demonstrated a positive relationship
with ERPF (regression equation: GFR = 37.3 + 0.150 ERPF)
(r2 68%, P < 0.001; Fig. 2), and an inverse association with
age (GFR = 177 to 1.14 age; r2 = 27%, P < 0.001; Fig. 3).
Likewise, a negative relationship was noted for ERPF with age
(ERPF = 835 to 5.75 age; r2 23%, P < 0.001; Fig. 4). Linear
regression analyses did not reveal significant bivariate relation-
ships for either GFR or ERPF with BMI, systolic or diastolic
blood pressures, HbAI or fasting levels of plasma glucose, total
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Fig. 1. Glomerular filtration rate and effective
renal plasma flow in non-insulin dependent
diabetics (NJDDMs) (N = 110) and normal
subjects (N = 32).
0.02 to 2.71; P > 0.18). Significant relationships were not
observed for filtration fraction for the NIDDMs with age, BMI,
blood pressures or the metabolic parameters (F values range:
0.06 to 2.42; P> 0.15).
Twenty (18%) of the NIDDMs demonstrated fundal changes
of diabetic retinopathy. In this group GFR and ERPF were 116
(23) and 549 (117) mllmin, which were similar to the respective
values of 117 (22) and 527 (123) ml/min observed for patients
without retinopathy. Satisfactory urine collections were ob-
tained in 91 patients. Median AER was 1.0 tg/min (range: 0.1 to
35). Six (6.6%) of the NIDDMs demonstrated AER in excess of
20 gJmin. AER did not demonstrate significant relationships
with GFR (P > 0.13), ERPF (P > 0.4) or FF (P > 0.7).
In the normal subjects, GFR demonstrated a positive rela-
tionship with ERPF (GFR = 35.6 + 0.125 ERPF; r2 = 50%, P
<0.001; Fig. 2), and a negative correlation was observed with
age (GFR = 137 to 0.82 age; r2 = 57%, P < 0.001; Fig. 3). ERPF
also demonstrated an inverse relationship with age (ERPF =
625 to 2.94 age; r2 23%, P < 0.01; Fig. 4). Neither GFR,
ERPF nor FF demonstrated significant relationships with BMI,
systolic and diastolic blood pressure or fasting plasma glucose.
The relationships between GFR and ERPF were similar for
the NIDDMs and normals. The difference in the slopes of the
regression analysis between the two parameters for the two
groups of 0.025 was not significant (95% confidence interval,
—0.024 to 0.074). The decline in GFR with age was also similar
for the two groups (difference in slopes = —3.2 mI/min/lO years;
95% confidence interval, —7.6 to 1.1). However, a significant
difference of —28.0 ml/min/l0 years was observed between the
slopes for the relationship between ERPF and age for the
NIDDMs and normals (95% confidence interval, —55.8 to
—0.34), indicating a greater decline in ERPF with advancing age
for the former group. Covariate adjustment of the renal param-
eters for the NIDDMs with values obtained for the normals
revealed greater GFR by 23 [4] mI/mm (P <0.001) and ERPF by
63 [20] mI/mm for the former group (P < 0.005). In keeping with
the elevated filtration fraction for the NIDDMs, analysis of
covariance demonstrated an elevation of GFR by 14 [31 mI/mm
over and above that explained by the increased ERPF (P <
0.001). Introduction of BMI, systolic or diastolic blood pres-
sures or the metabolic parameters as covariates did not reveal a
significant contribution to the observed differences in GFR and
ERPF between the NIDDMs and normals.
As the bivariate relationships described above may have been
modified by other study variables, multivariable regression
analysis was performed for the NIDDMs. With GFR as the
dependent variable, ERPF was the strongest explanatory vari-
able (P < 0.001), followed by the age of the patient (P < 0.01).
BMI, systolic or diastolic blood pressure and the metabolic
parameters did not contribute significantly to the regression
model (P > 0.1). Thereafter, a regression equation was formu-
lated as GFR = 63.9 + 0,136 ERPF — 0.363 age (r2 = 70.1%, P
Fig. 2. Relationship between glomerular1000 filtration rate and effective renal plasma flow
in non-insulin dependent diabetics (NIDDMs)
(N = 110) and normal subjects (N = 32).
Fig. 3. Relationship between glomerular20 30 40 50 60 70 80 filtration rate and age in non-insulin
dependent diabetics (NIDDMs) (N =110) and
Age, years normal subjects (N = 32).
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<0.001). Multivariable regression analysis, with ERPF as the
dependent variable, revealed age as the only significant explan-
atory variable (r2 = 22.1%, P < 0.001).
Discussion
Little information is available regarding renal hemodynamics
in NIDDMs, especially prior to the development of overt
nephropathy. GFR has been reported as "normal" (greater
than 80 ml/min/l .73 m2) in over 50% of NIDDMs in a cross
sectional study which included patients with other diseases [51.
In a small group of NIDDMs, with known disease duration of 0
to 15 years, GFRs were comparable to age-matched normals
[271. More recently, evaluation of GFR and ERPF in Black
American NIDDMs suggests the presence of hyperfiltration
(GFR values above 140 ml/min/1 .73 m2) in one-third of a small
group of patients with known disease duration of less than one
year [28]. However, the high incidence of ESRD in such ethnic
groups of patients precludes generalization to all NIDDMs [29,
301.
Newly presenting, normotensive NIDDMs of Caucasian ori-
gin demonstrated a wide range of GFR and ERPF levels. The
observed ranges of renal heniodynamics may reflect not only
the broad distribution of age but also the unknown duration of
glucose intolerance prior to diagnosis of NIDDM. Both GFR
and ERPF were significantly greater for the NIDDMs compared
with a group of normal subjects of similar age range. GFRs in
excess of 140 ml/min/1.73 m2 were observed in 16% of the
patients. As the filtration rate declines with age in normals [31,
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a









































32], it is more appropriate to compare GFR in the NIDDMs
with normal subjects of similar age range. More importantly,
therefore, GFR values in excess of mean + 2 standard devia-
tions of the normals (120 ml/min/l.73 m2) were observed in 45%
of the NIDDMs. A similar prevalence of glomerular hyperfil-
tration has been reported in short-term IDDMs 1331.It has been
proposed that such hyperfunction is a predictor for subsequent
development of nephropathy [34], although such a hypothesis is
not uniformly accepted [35]. A predisposition to hypertension,
as evidenced by increased erythrocyte sodium-lithium counter-
transport, has been reported in hyperfiltrating IDDMs [36]. In
our study, however, systolic and diastolic blood pressures were
similar for groups of NIDDMs with GFR values above or below
120 mi/mm.
The relationship between GFR and ERPF, that is the slope of
the regression analysis, was similar for the NIDDMs and
normals. For both groups of subjects, GFR was inversely
correlated with age. The rate of decline of GFR with age was
similar for the two groups. The range of GFR values observed
in the normals is consistent with previous reports, as is the
decline of 8 to 10 mI/mm per decade of advancing age [31, 32].
Similarly, ERPF was inversely related with age for the NID-
DMs and normals. The decline in ERPF with advancing age
was, however, greater in the NIDDMs than the normals. Such
a cross sectional relationship may result from an impaired
vasodilatory capacity in response to hyperglycemia in the older
NIDDMs. Significant bivariate relationships were not observed
for either GFR or ERPF for the NIDDMs with BMI, systolic or
diastolic blood pressures, fasting plasma glucose, HbAI, total
cholesterol, HDL-choiesterol, LDL-cholesterol or triglyceride
levels. Furthermore, modelling of all the parameters simulta-
neously, with GFR as the dependent variable, revealed ERPF
and age to be the significant explanatory variables. For ERPF,
multivariable regression analysis demonstrated age as the only
significant explanatory variable.
Concerning retinopathy, 18% of our study population dem-
onstrated fundal changes of diabetes. This prevalence is com-
parable to the 23% reported for newly presenting NIDDMs
entering the United Kingdom Prospective Diabetes Study, in
which hypertensive subjects were also included [37]. The
prevalence of microalbuminuria (AER 20 to 200 sgImin) of 7%
in the normotensive patients in this study is lower than previ-
ously reported in newly presenting NIDDMs [38—40]. These
latter studies have variously included subjects with hyperten-
sion and other concommittant diseases known to increase
urinary albumin excretion. The relationship of AERs with
hyperglycemia and metabolic parameters, including lipid levels,
is the subject of a separate report.
In the NIDDMs, neither GFR nor ERPF demonstrated sig-
nificant relationships with either fasting plasma glucose on the
day of estimation of the renal parameters or with glycosylated
hemoglobin levels. In these patients, however, the duration of
glucose intolerance prior to clinical presentation cannot be
assessed. The relationships between the renal parameters and
lipid levels were examined because of the possible role of
abnormal lipid metabolism in the development and progression
of renal disease [411. Experimental studies have demonstrated
that such abnormal lipid metabolism, specifically hypercholes-
terolemia, may modulate glomerular injury [41]. In our patient
group, elevated cholesterol and triglyceride levels were ob-
served in 35 and 40%, respectively, which are comparable to
previously reported prevelances in newly presenting NIDDMs
[42]. However, despite the possible lengthy duration of NIDDM
prior to diagnosis, renal parameters in our patient group were
not correlated with lipid or fasting plasma glucose levels. The
absence of such relationships in a cross sectional study does not
exclude a contribution of hyperglycemia or abnormal lipid
metabolism to any subsequent changes in renal function, ob-
served during longitudinal assessment of this patient group.
Other factors that have been implicated in the pathogenesis of
diabetic renal disease are deranged glomerular hemodynamics
and/or glomerular hypertrophy [42—45]. Early stages of human
and experimental IDDM are characterized by an elevation of
GFR and ERPF [33, 34, 43—45]. It has been proposed that such
glomerular hyperfunction may play a pivotal part in the initia-
tion and progression of diabetic glomerulopathy [34, 43—45].
Studies in experimental diabetes reveal a comparable rise in
single nephron GFR [43—45]. Single nephron hyperfiltration
results from an elevation of glomerular capillary plasma flow
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Fig. 4. Relationship between effective renal20 30 40 50 60 70 80 plasma flow and age in non-insulin dependent
diabetics (NIDDMs) (N = 110) andnormal
Age, years subjects (N = 32).
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than efferent arteriolar resistance [43—451. That such glomerular
hypertension may result in later glomerular obsolescence is
suggested by findings that amelioration of these abnormalities,
by dietary protein restriction or angiotensin converting enzyme
inhibition, is associated with delayed development of glomeru-
lopathy [43—45]. More recently, attention has been focused on
the role of glomerular enlargement per se in the pathogenesis of
progressive glomerular damage [46, 47]. Whether glomerular
hypertension or hypertrophy are independent risk factors for
progressive glomerular injury, however, remains a subject of
much debate [48].
The NIDDMs in the present study demonstrated higher
GFRs and filtration fractions compared with the normals.
Indeed, covariate adjustment revealed that less than 50% of the
increase in GFR could be accounted for by the elevated ERPF.
Of the determinants of GFR, based on micropuncture studies
[491, the raised filtration fraction suggests a relative increase in
glomerular capillary pressure and/or ultrafiltration coefficient in
the NIDDMs. The greater decline in ERPF with advancing age
in the NIDDMs compared with the normals, in the presence of
similar rates of reduction of GFR with age for the two groups,
suggests the presence of increased glomerular capillary pres-
sure and/or ultrafiltration coefficient even in the older NIDDMs.
Such abnormalities would therefore be superimposed on declin-
ing renal mass and increasing sclerotic glomeruli associated
with advancing age [50]. Furthermore, such abnormalities may
have been present for a considerable period during undiagnosed
glucose intolerance.
Major deficiencies exist in our understanding of the natural
history of diabetic renal dysfunction as related to the NIDDM
group of patients. On-going longitudinal evaluation of our
patient group should establish the role of the observed renal
hemodynamic abnormalities at presentation and their relation-
ship to metabolic changes in the subsequent development of
nephropathy in NIDDMs.
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